공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

호중구 엘라스타제 : 파이프라인 리뷰

Neutrophil Elastase - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 365751
페이지 정보 영문 65 Pages
가격
US $ 3,500 ₩ 3,904,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,809,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,714,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


호중구 엘라스타제 : 파이프라인 리뷰 Neutrophil Elastase - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 65 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

호중구 엘라스타제(Neutrophil Elastase)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 전해드립니다.

1. 서론

  • 조사 범위

2. 호중구 엘라스타제 개요

3. 치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

4. 파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 초기 단계 제품

5. 기업에서 개발중인 제품

6. 대학/기관에서 개발중인 제품

7. 치료제 평가

  • 단일요법 제품/복합제별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

8. 치료제 개발에 참여하고 있는 기업

  • Cantex Pharmaceuticals, Inc.
  • Chiesi Farmaceutici SpA
  • Kamada Ltd.
  • Polyphor Ltd.

9. 약제 개요

10. 휴지 상태인 프로젝트

11. 개발이 중지된 제품

12. 주요 뉴스 및 프레스 릴리스

13. 부록

14. 도표

LSH 16.08.22

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by Chiesi Farmaceutici SpA, H2 2019
  • Pipeline by Chimerix Inc, H2 2019
  • Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
  • Pipeline by LifeMax Laboratories Inc, H2 2019
  • Pipeline by pH Pharma Co Ltd, H2 2019
  • Pipeline by Proteo Inc, H2 2019
  • Pipeline by Santhera Pharmaceuticals Holding AG, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

According to the recently published report 'Neutrophil Elastase - Pipeline Review, H2 2019'; Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Neutrophil elastase is a serine proteinase. It is secreted from neutrophils. It is involved in inflammatory diseases, including idiopathic pulmonary fibrosis, rheumatoid arthritis, adult respiratory distress syndrome, and cystic fibrosis. It modifies the functions of natural killer cells, monocytes and granulocytes. It inhibits C5a-dependent neutrophil enzyme release and chemotaxis.

The report 'Neutrophil Elastase - Pipeline Review, H2 2019' outlays comprehensive information on the Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Discovery stages are 6, 1 and 1 respectively.

Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Respiratory, Immunology, Genetic Disorders, Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Infectious Disease and Metabolic Disorders which include indications Cystic Fibrosis, Inflammation, Alpha-1 Antitrypsin Deficiency (A1AD), Bronchiectasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bronchiolitis Obliterans, Chronic Obstructive Pulmonary Disease (COPD), Graft Versus Host Disease (GVHD), Ischemia Reperfusion Injury, Lung Disease, Lung Injury, Lung Transplant Rejection, Myelodysplastic Syndrome, Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), Non-Alcoholic Steatohepatitis (NASH), Primary Ciliary Dyskinesia, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Traumatic Brain Injury, Type 2 Diabetes and Vascular Injury.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)
  • The report reviews Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Overview
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Chiesi Farmaceutici SpA
  • Chimerix Inc
  • Kyorin Pharmaceutical Co Ltd
  • LifeMax Laboratories Inc
  • pH Pharma Co Ltd
  • Proteo Inc
  • Santhera Pharmaceuticals Holding AG
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Drug Profiles
  • alvelestat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CHF-6333 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dociparstat sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KRP-109 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LM-030 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PHP-303 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • POL-6014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sivelestat sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule 1 to Inhibit ELANE for Immunology, Oncology and Respiratory Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ELANE for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Neutrophil Elastase for Lung Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tiprelestat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Dormant Products
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Discontinued Products
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting
  • Nov 13, 2019: LifeMax receives Orphan Drug Designation from the European Commission for LM-030 for the treatment of Netherton Syndrome
  • Sep 10, 2019: Santhera announces publication of phase I clinical data with POL6014 in Journal of Cystic Fibrosis
  • Jul 18, 2019: LifeMax receives rare pediatric disease designation for LM-030 for the treatment of netherton syndrome
  • Jun 27, 2019: LifeMax receives orphan drug designation from the United States Food & Drug Administration for LM-030 for the treatment of Netherton Syndrome
  • Nov 05, 2018: First patient dosed in phase 2 alpha-1 antitrypsin deficiency study
  • Oct 24, 2018: Santhera announces start of phase Ib/IIa trial with POL6014 in patients with cystic fibrosis
  • Oct 15, 2018: Santhera receives positive opinion for Orphan Drug Designation in the EU for POL6014 in Cystic Fibrosis
  • Sep 13, 2018: LifeMax appoints Laman Alani, Ph.D., as VP of Product Development
  • Jun 04, 2018: Cantex Pharmaceuticals Announces That Clinical Trial Data For CX-01 In Refractory Acute Myeloid Leukemia And Myelodysplastic Syndrome Will Be Presented At The 2018 ASCO Annual Meeting
  • Mar 12, 2018: Publication in Blood Advances Reports that the Combination of Cantex Pharmaceuticals CX-01 with Chemotherapy for the Treatment of Acute Myeloid Leukemia Showed Encouraging Complete Remission Rates and Rapid Platelet Count Recovery
  • Jan 03, 2018: Cantex Pharmaceuticals Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
  • Jun 06, 2016: Polyphor successfully completes clinical Phase I study with POL6014 targeting life threatening lung diseases including cystic fibrosis
  • Jun 06, 2016: Proteo receives US$ 1 million grant for a new Elafin drug formulation
  • Mar 23, 2016: Polyphor announces $3 Million Award from Cystic Fibrosis Foundation Therapeutics to advance the clinical development of POL6014
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q